AR119376A1 - Compuestos heterocíclicos - Google Patents

Compuestos heterocíclicos

Info

Publication number
AR119376A1
AR119376A1 ARP200101928A ARP200101928A AR119376A1 AR 119376 A1 AR119376 A1 AR 119376A1 AR P200101928 A ARP200101928 A AR P200101928A AR P200101928 A ARP200101928 A AR P200101928A AR 119376 A1 AR119376 A1 AR 119376A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
halo
aryl
halogen
Prior art date
Application number
ARP200101928A
Other languages
English (en)
Inventor
Hans Richter
Fionn Ohara
Uwe Grether
Benoit Hornsperger
Bernd Kuhn
Maurice Biedermann
Miroslav Kosar
Flore Reggiani
Carsten Kroll
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67220669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR119376(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR119376A1 publication Critical patent/AR119376A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Reivindicación 1: Compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo, en la que: X es -CH₂CR³R⁴- o -CH=CR³ -, Y es -O-, -S-, -SO-, o -SO₂-, R¹ es arilo C₆₋₁₄ o heteroarilo de 5 a 14 elementos, en el que dicho arilo C₆₋₁₄ o heteroarilo de 5 a 14 elementos se sustituye opcionalmente con 1 a 5 sustituyentes seleccionados independientemente de alquilo C₁₋₆, alcoxi C₁₋₆, halo-alquilo C₁₋₆, halo-alcoxi C₁₋₆, halógeno, ciano, hidroxi y un grupo de fórmula (2), R² es hidrógeno o alquilo C₁₋₆, R³ es un grupo de fórmula (3), R⁴ es hidrógeno, halógeno o hidroxi, R⁵ es hidrógeno, halógeno, hidroxi, amino, halo-alquilo C₁₋₆, alcoxi C₁₋₆, alquilo C₁₋₆, halo-alcoxi C₁₋₆, ciano o oxo, R⁶ es hidrógeno, halógeno, arilo C₆₋₁₄, heteroarilo de 5 a 14 elementos, haloalcoxi C₁₋₆, halo-alquilo C₁₋₆, oxo, alquilo C₁₋₆, alcoxi C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₁₄ o ciano, en el que dicho heteroarilo de 5 a 14 elementos o arilo C₆₋₁₄ se sustituye opcionalmente con 1 a 2 sustituyentes seleccionados de halógeno, ciano, amino, hidroxi, alquilo C₁₋₆ y alcoxi C₁₋₆, A y B son, cada uno independientemente, heteroarilo de 5 a 14 elementos, arilo C₆₋₁₄, heterociclilo de 3 a 14 elementos o cicloalquilo C₃₋₁₄, y n y p son, cada uno independientemente, 1, 2, 3, 4 ó 5.
ARP200101928A 2019-07-09 2020-07-08 Compuestos heterocíclicos AR119376A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19185088 2019-07-09

Publications (1)

Publication Number Publication Date
AR119376A1 true AR119376A1 (es) 2021-12-15

Family

ID=67220669

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101928A AR119376A1 (es) 2019-07-09 2020-07-08 Compuestos heterocíclicos

Country Status (19)

Country Link
US (1) US12662490B2 (es)
EP (1) EP3997096B1 (es)
JP (1) JP7649283B2 (es)
KR (1) KR20220034104A (es)
CN (1) CN114096545A (es)
AR (1) AR119376A1 (es)
AU (1) AU2020311584A1 (es)
BR (1) BR112021026899A2 (es)
CA (1) CA3145338A1 (es)
CL (1) CL2022000019A1 (es)
CO (1) CO2022000186A2 (es)
CR (1) CR20220004A (es)
IL (1) IL288987A (es)
MX (1) MX2022000243A (es)
PE (1) PE20220515A1 (es)
PH (1) PH12021553249A1 (es)
TW (1) TW202116781A (es)
WO (1) WO2021005034A1 (es)
ZA (1) ZA202110352B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737680A1 (en) 2018-01-08 2020-11-18 F. Hoffmann-La Roche AG Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
MY210507A (en) 2018-08-13 2025-09-28 Hoffmann La Roche New heterocyclic compounds as monoacylglycerol lipase inhibitors
WO2020104494A1 (en) 2018-11-22 2020-05-28 F. Hoffmann-La Roche Ag New heterocyclic compounds
CN114072405A (zh) 2019-07-03 2022-02-18 豪夫迈·罗氏有限公司 杂环单酰基甘油脂肪酶(magl)抑制剂
KR20220034104A (ko) 2019-07-09 2022-03-17 에프. 호프만-라 로슈 아게 신규 헤테로고리 화합물
PH12022550339A1 (en) 2019-09-12 2023-03-13 Hoffmann La Roche 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
PE20231372A1 (es) 2020-09-03 2023-09-07 Hoffmann La Roche Compuestos heterociclicos

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK116181A (da) 1980-04-11 1981-10-12 Hoffmann La Roche Fremgangsmaade til fremstilling af quinolizidinderivater
FI77852C (fi) 1981-02-17 1989-05-10 Otsuka Pharma Co Ltd Foerfarande foer framstaellning av nya, saosom hjaertmediciner anvaendbara substituerade amid- och (maettad heterocykel)karbonylkarbostyrilderivat.
US4956359A (en) 1985-02-28 1990-09-11 A. H. Robins Company, Inc. 3-aryloxy and 3-arylthioazetidinecarboxamides as anticonvulsants and antiepileptics
US4632925A (en) 1985-10-07 1986-12-30 Hoffmann-La Roche Inc. N-substituted diphenylpiperidines and antiobesity use thereof
US6673908B1 (en) 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
GB9917385D0 (en) 1999-07-23 1999-09-22 Cerebrus Ltd Chemical compounds-I
TW200402417A (en) 2002-06-21 2004-02-16 Akzo Nobel Nv 1-[(Indol-3-yl)carbonyl]piperazine derivatives
AU2004234125A1 (en) 2003-05-01 2004-11-11 Vernalis Research Limited Azetidinecarboxamide derivatives and their use in the treatment of CB1 receptor mediated disorders
US7579495B2 (en) 2003-12-19 2009-08-25 Momentive Performance Materials Inc. Active-releasing cyclic siloxanes
DE602005024677D1 (de) 2004-04-22 2010-12-23 Memory Pharm Corp Indole, 1h-indazole, 1,2-benzisoxazole, 1,2-benzoisothiazole, deren herstellung und verwendungen
BRPI0512567A (pt) 2004-06-22 2008-03-25 Pfizer Prod Inc compostos antagonistas de receptor de histamina-3 diazabicìclico e respectivas composições farmacêuticas
WO2006051410A1 (en) 2004-11-15 2006-05-18 Pfizer Inc. Azabenzoxazoles for the treatment of cns disorders
CA2609957A1 (en) 2005-06-20 2007-01-04 Schering Corporation Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists
EP1984351A1 (en) 2006-02-17 2008-10-29 Memory Pharmaceuticals Corporation Compounds having 5-ht6 receptor affinity
WO2007117557A2 (en) 2006-04-05 2007-10-18 Vitae Pharmaceuticals, Inc. Diaminopropanol renin inhibitors
JP2010520217A (ja) 2007-03-01 2010-06-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンｈ３受容体のモジュレーターとしてのテトラヒドロイソキノリン化合物
PE20091017A1 (es) 2007-10-31 2009-07-16 Janssen Pharmaceutica Nv Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno a4 hidrolasa
GB0724251D0 (en) 2007-12-12 2008-02-06 Univ Edinburgh Therapeutic compounds and their use
GB0804685D0 (en) 2008-03-13 2008-04-16 Univ Edinburgh Therapeutic compounds and their use
EP2408772B1 (en) 2009-03-19 2015-07-01 Medical Research Council Technology Compounds
WO2011059118A1 (ko) 2009-11-10 2011-05-19 Kim Hyun Jeen 후각인지능력 검사 시스템
WO2012155199A1 (en) 2011-05-16 2012-11-22 Bionomics Limited Amine derivatives as potassium channel blockers
ES2605164T3 (es) * 2011-08-19 2017-03-13 Merck Sharp & Dohme Corp. Inhibidores del canal de potasio de la médula renal externa
WO2013059118A1 (en) 2011-10-19 2013-04-25 The Trustees Of Columbia University In The City Of New York Cyclopropenimine catalyst compositions and processes
NZ627750A (en) 2012-01-06 2016-11-25 Abide Therapeutics Inc Carbamate compounds and of making and using same
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
WO2014099633A2 (en) * 2012-12-19 2014-06-26 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2015179559A2 (en) 2014-05-21 2015-11-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
US10570146B2 (en) 2014-07-25 2020-02-25 Northeastern University Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof
WO2016109501A1 (en) 2014-12-30 2016-07-07 Karos Pharmaceuticals, Inc. Amide compounds as tryptophan hydroxylase inhibitors
US10106556B2 (en) 2015-03-30 2018-10-23 Takeda Pharmaceutical Company Limited Heterocyclic compound
US20180148429A1 (en) 2015-05-13 2018-05-31 Selvita S.A. Substituted quinoxaline derivatives
WO2016185279A1 (en) 2015-05-21 2016-11-24 Glaxosmithkline Intellectual Property Development Limited Benzoimidazole derivatives as pad4 inhibitors
PT3312177T (pt) 2015-06-09 2021-05-17 Onconic Therapeutics Inc Composto derivado tricíclico, método para preparar o mesmo e composição farmacêutica compreendendo o mesmo
EP3310773B1 (en) 2015-06-18 2020-12-02 89Bio Ltd. Substituted 4-benzyl and 4-benzoyl piperidine derivatives
US10323038B2 (en) * 2015-11-20 2019-06-18 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
US10519134B2 (en) 2015-11-20 2019-12-31 Lundbeck La Jolla Research Center, Inc. Pyrazole compounds and methods of making and using same
WO2017087858A1 (en) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
UY37174A (es) 2016-03-31 2017-10-31 Takeda Pharmaceuticals Co Un compuesto heterocíclico que tiene una acción inhibidora de monoacilglicerol lipasa
WO2017170830A1 (ja) 2016-03-31 2017-10-05 武田薬品工業株式会社 複素環化合物
JP2020506903A (ja) * 2017-01-23 2020-03-05 ファイザー・インク Ｍａｇｌ阻害薬としての複素環式スピロ化合物
JOP20190267A1 (ar) * 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl
UA126685C2 (uk) * 2017-08-29 2023-01-11 Луннбек Ла-Холья Рісьоч Сенте, Інк. Сполуки, які є модуляторами magl, і способи їх отримання і застосування
AU2018338855B2 (en) 2017-09-29 2022-04-28 Takeda Pharmaceutical Company Limited Heterocyclic compound
AR114136A1 (es) 2017-10-10 2020-07-29 Hoffmann La Roche Compuestos heterocíclicos
EP3717477B1 (en) 2017-11-28 2022-07-20 F. Hoffmann-La Roche AG New heterocyclic compounds
US11498923B2 (en) 2017-12-13 2022-11-15 Merck Sharp & Dohme Llc Substituted imidazo[1,2-c]quinazolines as A2A antagonists
TW201930300A (zh) 2017-12-15 2019-08-01 瑞士商赫孚孟拉羅股份公司 新雜環化合物
EP3737680A1 (en) 2018-01-08 2020-11-18 F. Hoffmann-La Roche AG Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
DK3768684T3 (da) 2018-03-22 2023-04-24 Hoffmann La Roche Oxazin-monoacylglycerol-lipase (MAGL)-hæmmere
MY210507A (en) 2018-08-13 2025-09-28 Hoffmann La Roche New heterocyclic compounds as monoacylglycerol lipase inhibitors
EP3837264A1 (en) 2018-08-13 2021-06-23 F. Hoffmann-La Roche AG New heterocyclic compounds as monoacylglycerol lipase inhibitors
WO2020104494A1 (en) 2018-11-22 2020-05-28 F. Hoffmann-La Roche Ag New heterocyclic compounds
EP3953360B1 (en) 2019-04-09 2024-02-28 F. Hoffmann-La Roche AG Heterocyclic compounds as inhibitors of monoacylglycerol lipase (magl)
CN114072405A (zh) 2019-07-03 2022-02-18 豪夫迈·罗氏有限公司 杂环单酰基甘油脂肪酶(magl)抑制剂
KR20220034104A (ko) 2019-07-09 2022-03-17 에프. 호프만-라 로슈 아게 신규 헤테로고리 화합물
US20210094971A1 (en) 2019-09-09 2021-04-01 Hoffmann-La Roche Inc. Heterocyclic compounds
WO2021048241A1 (en) 2019-09-12 2021-03-18 F. Hoffmann-La Roche Ag Radiolabeled compounds
PH12022550339A1 (en) 2019-09-12 2023-03-13 Hoffmann La Roche 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
MX2022003023A (es) 2019-09-23 2022-04-07 Hoffmann La Roche Compuestos heterociclicos.
WO2021058443A1 (en) 2019-09-24 2021-04-01 F. Hoffmann-La Roche Ag Fluorescent probes for monoacylglycerol lipase (magl)
CA3152213A1 (en) 2019-09-24 2021-04-01 F. Hoffmann-La Roche Ag New heterocyclic monoacylglycerol lipase (magl) inhibitors
MX2022002831A (es) 2019-09-24 2022-04-06 Hoffmann La Roche Compuestos heterociclicos.
WO2022043284A1 (en) 2020-08-26 2022-03-03 F. Hoffmann-La Roche Ag Heterocyclic compounds useful as magl inhibitors
PE20231372A1 (es) 2020-09-03 2023-09-07 Hoffmann La Roche Compuestos heterociclicos
AU2022260537A1 (en) 2021-04-23 2023-09-21 F. Hoffmann-La Roche Ag Heterocyclic compounds

Also Published As

Publication number Publication date
CO2022000186A2 (es) 2022-01-17
CR20220004A (es) 2022-01-31
WO2021005034A1 (en) 2021-01-14
AU2020311584A1 (en) 2022-01-20
PE20220515A1 (es) 2022-04-07
IL288987A (en) 2022-02-01
MX2022000243A (es) 2022-02-03
EP3997096A1 (en) 2022-05-18
CN114096545A (zh) 2022-02-25
BR112021026899A2 (pt) 2022-05-10
US20220242876A1 (en) 2022-08-04
ZA202110352B (en) 2022-08-31
US12662490B2 (en) 2026-06-23
EP3997096C0 (en) 2024-08-28
PH12021553249A1 (en) 2023-02-27
JP2022539604A (ja) 2022-09-12
TW202116781A (zh) 2021-05-01
EP3997096B1 (en) 2024-08-28
JP7649283B2 (ja) 2025-03-19
KR20220034104A (ko) 2022-03-17
CA3145338A1 (en) 2021-01-14
CL2022000019A1 (es) 2022-10-21

Similar Documents

Publication Publication Date Title
AR110405A1 (es) Compuestos
AR104884A1 (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
AR121044A1 (es) Inhibidores de egfr
AR114793A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos
AR100645A1 (es) Derivados de pirazolo-pirimidina
AR113842A1 (es) Derivados de tiazol microbiocidas
AR109179A1 (es) Inhibidores de diacilglicerol aciltransferasa 2
AR113929A1 (es) Compuestos heterocíclicos
CO6321244A2 (es) Pirrolopiridinas como inhibidores de cinasa
AR099498A1 (es) Compuestos de triazina y su uso farmacéutico
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
AR091208A1 (es) Derivados de piperidina
AR099789A1 (es) Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
AR120868A1 (es) Tiofen-2-carboxamidas sustituidas y ácidos tiofen-2-carboxílicos sustituidos y sus derivados
AR119790A1 (es) Compuestos de isoxazolina y su uso como agentes para el control de plagas
AR122517A1 (es) Isoxazolidinas como inhibidores de ripk1 y usos de las mismas
AR109711A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR090557A1 (es) DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
AR115085A1 (es) DERIVADOS DE 3-AMINO-2,4,6-TRIAZINA COMO INHIBIDORES DE LA TIROSINA CINASA DE BRUTON (Btk)
AR116906A1 (es) Derivados de heteroarilo bicíclico
AR120864A1 (es) Tiofenocarboxamidas sustituidas y sus derivados
AR122726A1 (es) Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismos
AR096161A1 (es) Derivados de triazina
AR111252A1 (es) Compuestos de isoxazol carboxamida y usos de los mismos
AR092792A1 (es) Derivados de dihidrofurano-azetadina como agentes antiparasitarios

Legal Events

Date Code Title Description
FA Abandonment or withdrawal